Loading...
•
Sep 30, 2020
Insulet Q3 2020 Earnings Report
Insulet reported a revenue increase of 22% year-over-year, driven by Omnipod revenue growth of 20%.
Key Takeaways
Insulet Corporation reported strong financial results for the third quarter of 2020, with revenue reaching $234.0 million, a 21.8% increase compared to the previous year. The company's performance exceeded expectations, driven by innovation and a recurring revenue model. Insulet raised its full-year revenue outlook and anticipates delivering its fifth consecutive year of 20% growth.
Third quarter revenue reached $234.0 million, up 21.8% year-over-year.
Total Omnipod revenue was $212.1 million, a 19.7% increase.
Net income amounted to $11.6 million, or $0.17 per diluted share.
Adjusted EBITDA was $42.3 million, representing 18.1% of revenue.
Revenue by Segment
Forward Guidance
For the quarter ending December 31, 2020, the Company expects revenue growth of 7% to 11%.
Positive Outlook
- Total Omnipod revenue growth of 10% to 14%
- U.S. Omnipod revenue growth of 10% to 14%
- International Omnipod revenue growth of 10% to 14%
Challenges Ahead
- Drug Delivery decline of 17% to 23%
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...